

MOLECULAR DIAGNOSTIC REQUEST FORM

PATIENT INFORMATION

NAME: _____
LAST NAME FIRST NAME

ID/PASSPORT NO: _____ DATE OF BIRTH: ____/____/____
DD MM YY

CLINICAL DIAGNOSIS: _____ GENDER FEMALE
 MALE

SAMPLE INFORMATION

DATE OF COLLECTION: ____/____/____ TIME: ____/____
DD MM YY HH MM

SAMPLE TYPE (Please select one) :

Blood, Specify (EDTA, clotted) First Voided Urine
 Paraffin Embedded Tissue (FFPE) Nasopharyngeal Aspirate / Swab
 EDTA Plasma Autocyte / ThinPrep
 Serum
 Swab, Specify Type: _____
 Tissue, Specify Type: _____
 Others, Specify Type: _____

REPORT INFORMATION

PHYSICIAN: _____
 INSTITUTION: _____
 PHONE: _____ FAX: _____
 SIGNATURE: _____ DATE(DD/MM/YY): _____

PATIENT CONSENT

Confirmation of patient informed consent for genetic testing

Please put a "✓" in the box(es) to indicate the test(s) to be performed.

NGS Panel

- GAIA@MPDNGS Panel (Cancer type : _____)
- ACTION@MPDNGS Panel (Cancer type : _____)
- LUNG@MPDNGS Panel
- ctLUNG@MPDNGS Panel
- COLON@MPDNGS Panel
- ctBREAST@MPDNGS Panel

Oncology Panel

- Brain Cancer Panel (MGMT Promoter Methylation & Chromosome 1p/19q Deletion)
- BRCA1 & BRCA2 Gene Comprehensive Study
- Breast Immunohistochemistry Panel (ER, PR, HER2 & Ki-67)
- Colorectal Cancer Panel (KRAS, NRAS, BRAF & MSI)
- Endometrial Adenocarcinoma Classification Panel (POLE, MMR IHC & p53 IHC)
- ESR1 (exon 8) & PIK3CA Gene Mutation Detection by NGS
- IDH1 & IDH2 Gene Mutation Detection
- KIT & PDGFRA Gene Mutation Detection
- KRAS & NRAS Gene Mutation Detection
- KRAS, NRAS & BRAF Gene Mutation Detection by NGS
- Lung Cancer Panel I (EGFR, ALK FISH & ROS1 FISH)
- Lung Cancer Panel II (BRAF, MET ex.14 skipping & ERBB2 (HER2) ex.20)
- Lung Cancer Panel III (EGFR, ALK IHC & ROS1 FISH)
- MAP2K1 (MEK1) & MAP2K2 (MEK2) Gene Mutation Detection
- Microsatellite Instability Test & MMR Immunohistochemistry

Oncology Testing

- AKT1 codon 17 Mutation Detection
- ALK Gene Rearrangement Detection by FISH
- BRAF codon V600 Mutation Detection
- CDKN2A/B Homozygous Deletion Detection by FISH
- Chromosome 1p/19q Deletion by FISH
- Claudin 18.2 Immunohistochemistry
- EGFR Gene Hotspot Mutation Detection (exons 18-21)
- EGFR Gene Amplification Detection by FISH
- ERBB2 (HER2) exon 20 Mutation Detection
- ERBB2 (HER2) Gene Amplification by FISH | Fixation time <6 hrs 6-72 hrs >72 hrs
- ERBB2 (HER2) Immunohistochemistry
- ESR1 Gene Hotspot Mutation Detection (exons 5, 7 & 8)
- FOLR1 Immunohistochemistry
- Histone 3 (H3-3A) Mutation Detection K27 G34
- HPV Detection and Genotyping (37 Genotypes) for FFPE
- HRAS Gene Hotspot Mutation Detection (exons 2-4)
- KIT Gene Hotspot Mutation Detection (exons 9, 11, 13, 14 & 17)
- KRAS Gene Hotspot Mutation Detection (exons 2-4)
- MAPK1 E322K Mutation Detection
- MET exon 14 Skipping Mutation Detection
- MET Gene Amplification Detection by FISH
- MGMT Promoter Methylation by Methylation Specific PCR
- Microsatellite Instability Test
- MMR Immunohistochemistry
- NRAS Gene Hotspot Mutation Detection (exons 2-4)
- p53 Immunohistochemistry
- PALB2 Gene Comprehensive Study

Oncology Testing (Cont.)

- PDGFRA Gene Hotspot Mutation Detection (exons 12 & 18)
- PDL1 Immunohistochemistry (22C3)
- PIK3CA Gene Hotspot Mutation Detection (exons 10 & 21)
- PIK3CA Gene Hotspot Mutation Detection [Extended] (exons 2, 3, 5, 8, 10 & 21)
- POLE Gene Hotspot Mutation Detection (exons 9-14)
- RET Gene Rearrangement Detection by FISH
- RET Gene Hotspot Mutation Detection (exons 5, 8, 10, 11, 13-16)
- ROS1 Gene Rearrangement Detection by FISH
- TERT Gene Promoter Mutation Detection

Foundation Medicine / Oncotype

- FoundationOne CDx (324 cancer-related genes)
- FoundationOne CDx & RNA (324 DNA & 318 RNA cancer-related genes)
- FoundationOne Liquid CDx (324 cancer-related genes)
- FoundationOne Monitor (324 cancer-related genes)
- FoundationOne Heme (406 DNA & 265 RNA cancer-related genes)
- Oncotype DX Breast Recurrence Score test
- Oncotype DX Colon Recurrence Score test

Hereditary Cancer Screening

- APC Gene Comprehensive Study
- BRCA1 & BRCA2 Gene Comprehensive Study
- BMPR1A Gene Comprehensive Study
- CDH1 Gene Mutation Detection
- CHEK2 1100delC Mutation Detection
- EPCAM Gene Deletion Study
- MLH1 Gene Comprehensive Study
- MMR Genes Promoter Methylation Detection
- MSH2 Gene Comprehensive Study
- MSH6 Gene Comprehensive Study
- MUTYH Gene Comprehensive Study
- PMS2 Gene Comprehensive Study
- PTEN Gene Comprehensive Study
- RET Gene Hotspot Mutation Detection
- SLC25A13 Gene Mutation Detection
- STK11 Gene Comprehensive Study
- SMAD4 Gene Comprehensive Study
- TP53 Gene Comprehensive Study
- VHL Gene Comprehensive Study
- Specific Gene Known Mutation Screening (Point Mutation, Small Deletion and Insertion)
- Hereditary Cancer Panel (154 cancer-related genes)

Pharmacogenomics

- CYP2C9 & VKORC1 Genotyping for Warfarin Treatment
- CYP2C19 Genotyping for Clopidogrel Treatment
- DPYD Genotyping for 5-FU Responsiveness
- HLA-B*1301 Genotyping for Dapsone, Baktar or Phenytoin Treatment
- HLA-B*1502 Genotyping for Carbamazepine Treatment
- HLA-B27 Genotyping
- HLA-B*5801 Genotyping for Allopurinol Treatment
- NUDT15 Genotyping for Thiopurine Drugs Treatment
- TPMT Genotyping for Thiopurine Drugs Treatment
- UGT1A1 Genotyping for Irinotecan Toxicity

Others Please Specify: _____

